Hemostemix Inc. (CVE:HEM – Get Free Report) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.06 and traded as high as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 3,824 shares traded.
Hemostemix Trading Down 7.1%
The firm’s 50-day simple moving average is C$0.06 and its 200 day simple moving average is C$0.07. The company has a debt-to-equity ratio of -66.09, a current ratio of 0.24 and a quick ratio of 0.48. The firm has a market capitalization of C$13.32 million, a price-to-earnings ratio of -3.25 and a beta of 0.22.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
